31 results
20-F/A
2023 FY
CYTO
Altamira Therapeutics Ltd
22 Apr 24
Annual report (foreign) (amended)
4:31pm
, Mr. Munoz and Ms. Schwarz satisfy the “independence” requirements set forth in Rule 10A-3 under the Exchange Act.
The audit committee is governed … regarding the independent auditor’s communications with the audit committee concerning independence;
confirming and evaluating the rotation of the audit
424B5
CYTO
Altamira Therapeutics Ltd
19 Jan 24
Prospectus supplement for primary offering
4:40pm
(United States) and the SEC independence standards. This may not be comparable to financial statements of United States (“U.S.”) companies.
We
424B5
kllht
8 Dec 21
Prospectus supplement for primary offering
4:37pm
424B5
oehd5b3
15 Jan 21
Prospectus supplement for primary offering
4:32pm
424B5
x5cyr3er
3 Dec 20
Prospectus supplement for primary offering
5:25pm
424B3
rmiqaxiamjfn4pzdpea4
20 Feb 19
Prospectus supplement
5:01pm
424B3
9uix 2gsbat7tt
15 Feb 19
Prospectus supplement
4:31pm
F-1/A
8cd0s67xjf8
13 Feb 19
Registration statement (foreign) (amended)
5:21pm
F-4/A
ava9xuzp4n
13 Feb 19
Registration of securities (foreign) (amended)
5:02pm
F-1
d9gr r9xj6nfb
1 Feb 19
Registration statement (foreign)
8:01am
424B3
6h1j0t9
29 Jan 19
Prospectus supplement
5:14pm
424B3
x78p4c
29 Jan 19
Prospectus supplement
5:08pm
6-K
24i2g56vmt7t
29 Jan 19
Current report (foreign)
5:01pm
F-4
4pbtu044m0assua6lm9d
29 Jan 19
Registration of securities (foreign)
8:09am